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AUF1/hnRNP D represses expression of VEGF
in macrophages
Abigail Fellowsa,b, Mary E. Griffina, Brenda L. Petrellaa,b, Lihui Zhonga, Fatemeh P. Parvin-Nejada,c,
Roy Favaa,b, Peter Morganellia,d, R. Brooks Robeya,e, and Ralph C. Nicholsa,b,d
a

Veterans Administration Research Service, White River Junction, VT 05009; bDepartment of Medicine, Dartmouth
Medical School, Hanover, NH 03755; cHoward Hughes Medical Institution Fellowship Program, Dartmouth College,
Hanover, NH 03755; dDepartment of Immunology and Microbiology and eDepartment of Physiology, Dartmouth
Medical School, Hanover, NH 03755

ABSTRACT Vascular endothelial growth factor (VEGF) is a regulator of vascularization in development and is a key growth factor in tissue repair. In disease, VEGF contributes to vascularization of solid tumors and arthritic joints. This study examines the role of the mRNAbinding protein AUF1/heterogeneous nuclear ribonucleoprotein D (AUF1) in VEGF gene
expression. We show that overexpression of AUF1 in mouse macrophage-like RAW-264.7
cells suppresses endogenous VEGF protein levels. To study 3′ untranslated region (UTR)–
mediated regulation, we introduced the 3′ UTR of VEGF mRNA into a luciferase reporter
gene. Coexpression of AUF1 represses VEGF-3′ UTR reporter expression in RAW-264.7 cells
and in mouse bone marrow–derived macrophages. The C-terminus of AUF1 contains arginine–glycine–glycine (RGG) repeat motifs that are dimethylated. Deletion of the RGG domain
of AUF1 eliminated the repressive effects of AUF1. Surprisingly, expression of an AUF1-RGG
peptide reduced endogenous VEGF protein levels and repressed VEGF-3′ UTR reporter activity in RAW-264.7 cells. These findings demonstrate that AUF1 regulates VEGF expression,
and this study identifies an RGG peptide that suppresses VEGF gene expression.
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INTRODUCTION
Vascular endothelial growth factor (VEGF) is a growth factor critical
for blood vessel growth (Ferrara, 2004). In addition, VEGF acts as a
cytokine that stimulates immune cells (Ferrara, 2004) and increases
vascular permeability (Fava et al., 1994). In development, VEGF is so
critical to blood vessel formation that deletion of one VEGF allele in
mice results in embryonic lethality (Ferrara, 2004). In adults, VEGF
acts in a limited and temporal way in processes that require the
This article was published online ahead of print in MBoC in Press (http://www
.molbiolcell.org/cgi/doi/10.1091/mbc.E11-06-0545) on February 29, 2012.
Address correspondence to: Ralph C. Nichols (ralph.c.nichols@dartmouth.edu).
Abbreviations used: aa, amino acid; AdOx, adenosine dialdehyde; AUF1, AUF1/
heterogeneous nuclear ribonucleoprotein D mRNA-binding protein; AURE, adenosine-uridine–rich element; BMDM, bone marrow–derived macrophage; GLUT1,
glucose transporter-1; HK2, hexokinase-2; hnRNP, heterogeneous nuclear ribonucleoprotein; LPS, lipopolysaccharide; Luc, luciferase; RGG, arginine–glycine–glycine; RRM, RNA recognition motifs; siRNA, small inhibitory RNA; TNF, tumor necrosis factor-α; UTR, untranslated region; VEGF, vascular endothelial growth
factor.
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formation of new tissue, such as wound healing (Bao et al., 2009),
the proliferative stage of the menstrual cycle (Critchley et al., 2001),
and bone repair (Holstein et al., 2011). In disease, neovascularization is key to the growth of solid tumors (Ferrara, 2004), loss of sight
in intraocular vascularization (Ferrara, 2004), and nourishing of inflamed tissue, including the arthritic joint (Paleolog, 2009) and atherosclerotic plaques (Salomonsson et al., 2002). Therapeutic treatments with VEGF to induce angiogenesis are being studied (Ferrara,
2004), as are therapies that block VEGF protein or VEGF receptors,
primarily in solid cancers (Ferrara, 2004).
In addition to modulating blood vessel growth, therapies targeting VEGF also affect activation of immune cells that bear VEGF receptors. The macrophage is a central mediator of the innate immune response and plays a critical role in inflammatory processes
(Gordon, 2007; Paleolog, 2009). Recent studies show that the macrophage combines the innate immune response (activation of Toll
receptors by bacteria/lipopolysaccharide [LPS]) with the adaptive
immune response (Fc-receptor recognition of immune complexes;
Rittirsch et al., 2009). VEGF activates a family of cellular receptors
(Hiratsuka et al., 2001). Acting as a cytokine, VEGF facilitates macrophage infiltration into inflamed sites (Fava et al., 1994). In blood
vessel growth, VEGFR-2 is the key receptor and is found on
Molecular Biology of the Cell

endothelial cells (Hiratsuka et al., 2001). Another receptor, VEGFR-1,
is also found on endothelial cells but is considered a decoy receptor
that down-regulates VEGF activity (Hiratsuka et al., 2001). The relationship between VEGF and macrophage activation has not been
explored in depth, in part because the macrophage expresses the
VEGFR-1 receptor (Flt-1) but not VEGFR-2 (Flk-1; Hiratsuka et al.,
2001). For these reasons, the role of VEGF activation of macrophages
must be seen not simply with respect to blood vessel growth, but
also in terms of a cytokine promoting macrophage entry into tissue
(vascular permeability) and activating macrophages through
VEGFR-1, perhaps by an autocrine mechanism.
Posttranscriptional regulation of gene expression is controlled by
sequence elements in mRNA and by mRNA-binding proteins that
recognize mRNA sequence elements. The mRNA regulatory protein
HuR controls VEGF translation by stabilizing VEGF mRNA (GoldbergCohen et al., 2002). In contrast, AUF1/heterogeneous nuclear ribonucleoprotein (hnRNP) D (AUF1) regulates many mRNAs by destabilizing mRNA, although stabilization of mRNA has also been reported
(Kiledjian et al., 1997; Sela-Brown et al., 2000). Genetic deletion of
AUF1 in the mouse results in multiple disease phenotypes, including endotoxic shock (Lu et al., 2006), pruritic inflammatory skin disease (Sadri and Schneider, 2009), and B cell dysfunction (Sadri et al.,
2010). However, the effect of AUF1 on VEGF gene expression has
not been studied. Translational regulation of VEGF gene expression
by other mRNA-regulatory proteins has been the subject of recent
review (Yoo et al., 2006), and adenosine-uridine–rich elements
(AUREs) have been characterized (Chen and Shyu, 1995; Xu et al.,
1997; Ray and Fox, 2007). Genetic separation of the VEGF 3′ untranslated region (UTR) from the coding region by insertion of a reporter gene resulted in embryonic lethality in mice, demonstrating
the importance of the 3′ UTR in regulating VEGF gene expression
(Miquerol et al., 2000). We previously identified a region of VEGF 3′
UTR that contains an AURE, and we hypothesized that the AU-rich
element affected gene expression (Du et al., 2006). We identified a
similar AU-rich region in the 3′ UTR of glucose transporter-1 (GLUT1)
mRNA (Griffin et al., 2004). A recent report shows that the AU-rich
element in human VEGF mRNA regulates gene expression by alternating secondary structures of RNA (Ray and Fox, 2007). These facts
led us to investigate the role of regulatory mRNA-binding proteins
that control translation of VEGF mRNA in macrophages.
This study evaluates the effects of AUF1 on expression of endogenous VEGF protein and VEGF 3′ UTR–dependent reporters. We
are the first to show that AUF1 affects endogenous VEGF protein
levels and VEGF-3′ UTR–dependent gene expression. To investigate
the mechanism of AUF1 action and identify novel regulators of
VEGF gene expression, we focus on a regulatory region of the AUF1
protein. The C-terminal region contains multiple arginine–glycine–
glycine (RGG) motifs in an RGG domain. The arginine residue in the
third RGG motif is enzymatically methylated on the guanidinium
side chain (Ong et al., 2004). The effects of blockade of arginine
methylation are examined. Finally, we design peptides modeled on
the AUF1 RGG domain and measure the effects on endogenous
VEGF protein levels and VEGF-3′ UTR–dependent reporter activity.
The identification of rationally designed peptide regulators of AUF1
may yield novel methods to repress VEGF gene expression.

RESULTS
AUF1 decreases VEGF protein levels
To determine whether the mRNA-binding protein AUF1 affects endogenous VEGF protein production, we cloned the p37 isoform of
human AUF1 into the pcDNA-3.1-V5-His expression construct.
Cultured RAW-264.7 macrophage-like cells were transfected with
Volume 23 April 15, 2012

FIGURE 1: Effects of overexpressing AUF1 on endogenous VEGF
protein levels. Cultured RAW-264.7 cells were grown to 50%
confluence and transfected with full-length AUF1 (AUF1) or the empty
parental vector pcDNA-3.1 (PC). After 4 h, cells were treated with LPS
for 18 h. Lysates were probed for VEGF and α-tubulin. Two of six
experiments are shown. For six experiments, VEGF protein
(normalized to α-tubulin) was decreased by 22% (p < 0.04).

AUF1 and, after 4 h, treated with LPS (50 ng/ml) for 18 h. As shown
in Figure 1, immunoblotting of VEGF protein levels shows that AUF1
decreased VEGF modestly (22%) but significantly. This result is especially interesting since not all cells are transfected successfully by
transient transfection.

The 3′ UTR region of VEGF represses reporter gene activity
To evaluate the role of the 3′ UTR of VEGF mRNA in gene expression, we created a luciferase reporter construct (Du et al., 2006). The
3′ UTR of VEGF mRNA destabilizes mRNA, and when the 3′ UTR of
VEGF mRNA is introduced into the 3′ UTR of a heterologous reporter gene, the reporter activity decreases in resting macrophages
(Du et al., 2006; Ray and Fox, 2007). When cells are activated, reporters with the VEGF-3′ UTR have increased activity (Du et al.,
2006; Ray and Fox, 2007). As shown in Figure 2, introducing the 3′
UTR of VEGF into the 3′ UTR of the parental firefly luciferase reporter (3.1-Luc) to create the VEGF-3′ UTR-Luc reporter decreased
gene activity in many cell types (Figure 2). The VEGF-3′ UTR decreased reporter activity in RAW-264.7 macrophage cells (60% decrease; Figure 2A), as previously reported (Du et al., 2006). The
VEGF-3′ UTR also decreased reporter activity in mouse primary
bone marrow–derived macrophages (BMDMs; 50% decrease; Figure 2B). The VEGF mRNA is regulated posttranscriptionally in the rat
kidney cell (Feliers et al., 2005), and the VEGF-3′ UTR reduced reporter activity in the rat kidney cell line NRK-52E by 80% (Figure 2C).
The reporter also showed reduced activity in the human embryonic
kidney (HEK-293) cell line (70% decrease; Figure 2D).

AUF1 decreases the activity of the VEGF-3′ UTR reporter
To determine whether AUF1 affects VEGF-3′ UTR–dependent expression, we cotransfected AUF1 in RAW-264.7 cells with the VEGF3′ UTR-Luc reporter. As shown in Figure 3A, overexpression of AUF1
decreased luciferase reporter activity by 45%. The mRNA of AUF1 is
alternatively spliced to produce four isoforms. The smaller isoforms
(p37 and p40) are more predominant in the cytoplasm and are likely
more important in regulation of mRNA stability (He and Schneider,
2006). Overexpression of the p40 isoform also reduced VEGF-3′
UTR-Luc activity (45% decrease; Figure 3B). Overexpression of AUF1
did not affect the activity of the parental reporter, 3.1-Luc (Supplemental Table S1).

AUF1 associates with VEGF mRNA
To determine whether AUF1 associates with VEGF mRNA in RAW264.7 cells, we immunoprecipitated AUF1 from RAW-264.7 cell
lysates and measured VEGF mRNA in the pulldown. The presence
AUF1 represses VEGF expression
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protein in macrophages, and future studies will
determine whether AUF1 interacts directly with
the VEGF mRNA.

Sequence homology of AUF1
To identify functional domains of AUF1, several
studies have used sequence analysis (DeMaria
et al., 1997; He and Schneider, 2006). To extend these studies, we identified regions of
AUF1-p37 that are homologous to other species. Homology analysis was performed using
BLAST (National Center for Biotechnology Information) and is shown in Figure 5A. Different
homologies were found for three regions, encoded by exons 1, 3–5, and 6 and 8. The AUF1p37 isoform lacks exons 2 and 7 (Figure 5B). As
shown in Figure 5B, the central region of AUF1
contains two RNA recognition motifs (RRMs)
that are highly conserved (Figure 5A). The Cterminal region, encoded by exons 6 and 8, is
also conserved, except for opossum and panda
FIGURE 2: Effects of the 3′ UTR of VEGF mRNA on reporter activity in multiple cell types.
(Figure 5A). The N-terminus shows many non(A) VEGF-3′ UTR-luciferase (VEGF-3′ UTR-Luc) or the empty parental vector (3.1-Luc) were
identical residues between species (Figure 5A),
transfected into RAW-264.7 cells using Lipofectamine 2000. Luciferase activity was measured with the most variation occurring in serine and
in cell lysates. (B) Bone marrow–derived macrophages were obtained from C57/Bl6 mouse
threonine residues. Studies have shown that
femurs and cultured in L-400 media. After 6 d, cells were trypsinized and transfected with
the N- and C-terminal regions contribute to,
VEGF-3′ UTR-Luc or 3.1-Luc by electroporation (Amaxa). (C) Normal rat kidney cells
but are not primarily involved in, RNA binding
(NRK-52E) were cultured for <30 passages and transfected with VEGF-3′ UTR-Luc or 3.1-Luc
(DeMaria et al., 1997). The N- and C-terminal
using Lipofectamine 2000. (D) HEK-293 cells were transfected with VEGF-3′ UTR-Luc or
regions are both candidate regulatory regions
3.1-Luc using Lipofectamine 2000. All transfections (A–D) were incubated for 18–24 h before
(DeMaria et al., 1997; He and Schenider, 2006),
cell lysis. Results are normalized to 3.1-Luc transfection, and are representative of two or
and the role of the C-terminus in AUF1 function
more experiments. Shown are mean and SD. p < 0.001 for A and C. p < 0.01 for B and D.
is the subject of this study. The amino acid
sequences of AUF1-p37 and other AUF1 regions are shown in
of AUF1 isoforms in the pulldown was confirmed by immunoblotFigure 5C.
ting (Figure 4A). AUF1 has been reported to act on multiple genes
(Mazan-Mamczarz et al., 2009), and PCR was performed to identify
C-Terminal RGG motifs
other AURE-containing mRNAs pulled down with AUF1. As shown
Many regulatory mRNA-binding proteins shuttle between the cytoin Figure 4B, PCR products for VEGF, GLUT1, and hexokinase-2
plasm and nucleus, and localization to the cytoplasm increases ef(HK2) could be amplified from cDNA prepared from anti-AUF1 pullfects on regulated mRNA (He and Schenider, 2006). The RGG repeat
downs. Pulldowns without and with anti-AUF1 antibody contained
protein motif affects cytoplasmic localization of another mRNAthe very abundant 18S RNA (Figure 4B). Beads alone (no anti-AUF1
binding protein, hnRNP A2 (Nichols et al., 2000). Arginine residues
antibody added) and pulldowns with sera (mouse, rat, goat, bovine)
in RGG motifs of hnRNP A2 are methylated, and blockade of methybrought down no VEGF mRNA. For comparison of VEGF mRNA aslation with adenosine dialdehyde (AdOx) eliminated preferential
sociated with AUF1, we performed parallel pulldowns with a control
nuclear localization of hnRNP A2 (Nichols et al., 2000). The RGG
antibody (anti-Tie2). By real-time PCR analysis, there was 3.6-folddomain in AUF1-p37 includes three RGG motifs within a 27–amino
greater VEGF mRNA associated with AUF1 than with the control.
acid (aa) sequence (Figure 5B), and the arginine in the third RGG
This result demonstrates that VEGF mRNA associates with AUF1
motif of AUF1 is dimethylated (Ong et al.,
2004). Treatment of several cell types with
AdOx did not affect cytoplasmic/nuclear localization of AUF1 (He and Schenider, 2006). However, AdOx treatment of RAW-264.7 cells affects AUF1 protein levels (see later discussion).

Deletion of N- or C-terminal region
affects AUF1 activity

FIGURE 3: Effects of overexpressing AUF1 on VEGF-3′ UTR-luciferase. Cultured RAW-264.7
cells were cotransfected with VEGF-3′ UTR-Luc and either AUF1-p37 (A) or AUF1-p40 (B).
After 24 h, cells were lysed and luciferase activity measured. Results are normalized to
transfection with pcDNA-3.1 and are representative of two or more experiments. Shown are
mean and SD. p < 0.001 for A and p < 0.0001 for B.
1416 | A. Fellows et al.

Previous studies showed that N- and C-terminal regions are required for maximal RNA binding (DeMaria et al., 1997). To determine
whether the N- and C-terminal regions are necessary for regulating VEGF gene expression in
RAW-264.7 cells, we deleted portions of the Nand C-termini from AUF1. The RGG domain
Molecular Biology of the Cell

FIGURE 4: Immunoprecipitation of mRNA associated with AUF1. (A)
AUF1 protein was isolated with anti-AUF1 antibody and protein A
beads and the pulldown analyzed for AUF1 protein. Control
pulldowns were performed with no anti-AUF1 antibody (No Ab). (B)
To identify mRNA associated with AUF1, RNA was purified from
pulldown beads and the cDNA amplified for VEGF, GLUT1, HK2, or
18S RNA. PCR products are shown.

and a nearby polyglutamine region (poly-Q) contribute to RNA
binding (DeMaria et al., 1997) and were removed (Figure 5B). The
AUF1-ΔQRGG mutant was expressed in RAW-264.7 cells and
showed a loss of the inhibitory effect on VEGF-3′ UTR-Luc reporter
activity (Figure 6A). Deletion of 21 aa in the N-terminal region within
an alanine-rich region (AUF1-Δ21-Ala; Figure 5B) also eliminated the
inhibitory effects on VEGF reporter (Figure 6B), as did a double deletant (AUF1-Δ21-Ala+ΔQRGG; Figure 6B). Deletions may reduce
affects on reporter activity by reducing deletant protein levels, and
protein levels of AUF1 deletants were measured next.

Effects of deletions on AUF1 protein levels
To determine whether N- or C-terminal deletions affect protein levels, full-length AUF1 or AUF1 deletants were expressed in RAW264.7 cells and immunoblotted with anti-V5 antibody. Deletion of
21 amino acids from the polyalanine region decreased AUF1 protein levels (Figure 7). However, protein levels of the AUF1-ΔQRGG
mutant were similar to those of full-length AUF1 (Figure 7). The
double deletant (AUF1-Δ21-Ala+ΔQRGG) was expressed at lower
levels, similar to the AUF1-Δ21-Ala deletant (Figure 7). Larger deletions of the polyalanine region (up to 34 aa) also reduced protein
levels (Supplemental Figure S1).
Proximal to the polyalanine region are candidate ubiquitination
sites, and deletion of the polyalanine motifs may affect protein degradation via ubiquitin-mediated proteasomal degradation. To evaluate whether proteasomal inhibition affected AUF1 or AUF1 deletants, cells were transfected and then treated with MG132.
Proteasomal inhibition increased endogenous AUF1-V5 levels (Supplemental Figure S2A). Protein levels of both the AUF1-∆21-Ala deletant and the AUF1-∆QRGG also increased with MG132, but the
increases were less (Supplemental Figure S2A). The double deletant
(AUF1-∆21+∆QRGG) was not affected by MG132 (Supplemental
Figure S2B), suggesting that both N- and C-terminal regions affect
proteasomal degradation of AUF1.
To determine whether decreased protein levels resulted from reduced transfection efficiency, in separate experiments, we cotransfected AUF1 or AUF1 deletants with a parental luciferase vector
(Renilla luciferase). The transfection efficiency of all constructs was
the same (Supplemental Figure S3). Finally, to evaluate whether the
protein levels result from changes in protein turnover, we performed
cycloheximide (CYX) inhibition studies (50 μg/ml for 0, 1, or 4 h).
Treatment with CYX inhibits protein translation, and the rate of proVolume 23 April 15, 2012

tein degradation can be measured. As shown in Figure 8, although
with CYX treatment the double deletant appeared to have more
rapid decay than the wild-type AUF1, the difference was not significantly different (Figure 8). Hence the two deletants with reduced
protein levels (AUF1-Δ21-Ala and AUF1-Δ21-Ala+ΔQRGG; Figure 7)
displayed decay similar as wild type. More studies are needed to
explain why the AUF1-Δ21-Ala and AUF1-Δ21-Ala+ΔQRGG deletant proteins are expressed at lower levels. To summarize these protein studies: 1) the loss of activity on VEGF reporters by deletants
lacking the N-terminal polyalanine region (Figure 6B) likely results
from reduced protein levels (by an unknown mechanism); and 2) loss
of activity on VEGF reporters by the AUF1-∆QRGG C-terminal deletant (Figure 6A) does not result from reduced levels of the deletant
protein.

Blockade of arginine methylation reduces AUF1 protein
To extend our analysis of the C-terminal regulatory region, we
next determined whether methylation of arginine residues affects
protein levels. Cultured RAW-264.7 cells were treated with an
arginine methylation inhibitor, AdOx, for 48 h. Both endogenous
AUF1 (Figure 9A) and AUF1-V5 (Figure 9B) protein levels were
decreased with AdOx treatment. However, the AUF1-ΔQRGG
mutant was less affected by AdOx treatment (Figure 9B). Hence
deletion of the QRGG region did not affect protein levels (Figure
7), but blockade of arginine methylation decreased AUF1 protein
levels by a mechanism that is not clear. Together these results
suggest that deletion of the QRGG motif is a functional deletion
and that arginine methylation is important to AUF1 protein
levels.

Effects of AUF1-RGG peptides on VEGF gene expression
The reported functions of the RGG domain in the C-terminal region include homodimer formation (Kajita et al., 1995), RNA binding (Raman et al., 2001), and protein–protein interaction with
regulatory proteins (Raman et al., 2001; He and Schneider, 2006).
We hypothesized that a peptide modeled on the C-terminus
might interfere with binding of AUF1 with its binding partners and
act as a dominant-negative peptide. Two AUF1-RGG peptides
were created in expression vectors. One peptide contains the region encoded by exons 6 and 8 (AUF1-Ex6+8; Figure 5B). The
second is a shorter peptide whose N-terminus begins at the polyglutamine sequence (AUF1-QRGG; Figure 5B). As shown earlier
(Figure 1), treatment of RAW-264.7 cells with full-length AUF1 decreased endogenous VEGF protein levels. To determine whether
expression of the RGG peptides affects endogenous VEGF expression, RAW-264.7 cells were transfected with the empty vector
(PC), the AUF1-QRGG peptide (QRGG), or the AUF1-Ex6+8 peptide (6+8). As shown in Figure 10, A and B, endogenous VEGF
levels were decreased by 35% (AUF1-Ex6+8) or 40% (AUF1QRGG). To determine whether the AUF1-RGG peptides affect expression of the VEGF-3′ UTR reporter, we cotransfected RAW264.7 cells with VEGF-3′ UTR-Luc together with AUF1-6+8 or
AUF1-QRGG. The amount of repression of reporter activity was
the same with AUF1-RGG peptides and full-length AUF1 (Figure
10C). As a negative control, a small scrambled peptide did not
affect reporter activity when compared with overexpressed AUF1
(Supplemental Figure S4). Hence peptides modeled on the RGG
domain of AUF1 are effective inhibitors of endogenous VEGF
gene expression and likely act by a 3′ UTR–mediated mechanism.
Future studies will identify the active motif in AUF1-RGG peptides
and further characterize the mechanism by which AUF1-RGG peptides repress VEGF gene expression.
AUF1 represses VEGF expression
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DISCUSSION
Vascular endothelial growth factor is critical
as a growth factor in blood vessel growth
and as a cytokine in immune cell activation
(Ferrara, 2004). Our studies (Du et al., 2006)
and the studies of others (De Bandt et al.,
2003) demonstrate that VEGF acts as a cytokine in macrophages, activating the cell
through VEGFR-1 (De Bandt et al., 2003).
Hence macrophages both respond to and
produce VEGF. In human disease, macrophage cells may exacerbate disease when
overactivated or may play a role in fighting
disease when killing bacteria or as tumorinfiltrating macrophages (Gordon, 2007;
Stockmann et al., 2008). Growth factor stimulation of macrophages leads to increased
VEGF gene transcription (Jiang and Liu,
2009) and stabilization of VEGF mRNA (Du
et al., 2006). This study demonstrates that
the mRNA-binding protein AUF1/hnRNP D
regulates expression of VEGF.
Expression of genes is primarily regulated by transcription acting on gene promoter and enhancer sequences. However,
genes that encode proteins involved in cell
activation, such as cytokines and growth factors, are often regulated posttranscriptionally (Xu et al., 1997). Posttranscriptional
regulatory steps include 1) splicing and processing, 2) nuclear export, 3) cytoplasmic
localization, 4) translational efficiency, and 5)
degradation (Ferrara, 2004). Our previous
studies show that a region of the 3′ UTR of
VEGF mRNA that contains an adenosineuridine–rich element regulates VEGF gene

FIGURE 5: (A) Sequence analysis of AUF1. Shown are comparisons of the nine most closely
related species with human AUF1-p37. Exons 2 and 7 are alternatively spliced out of the p37
isoform. Vertical lines show single–amino acid variations or single–amino acid gaps as compared
1418 | A. Fellows et al.

with human. (B) Diagram showing the
structure of AUF1, including two polyalanine
motifs (poly-Ala; 11-AAAAA-15 and
37-AAAAA-41), two RRMs, a polyglutamine
stretch (poly-Q; 245-QQQQQ-249), and three
RGG repeats (253-RGG-255, 263-RGG-265,
and 277-RGG-279). Alternative splicing that
retains exon 2, exon 7, or both produces the
other AUF1 isoforms (AUF1-p40, -p42, -p45;
not shown). Below are shown AUF1 deletion
constructs and AUF1-RGG peptides:
AUF1-Δ21-Ala (aa 13–33 deleted), AUF1ΔQRGG (aa 206–280 deleted), AUF1-Ex6+8
(aa 234–287), and AUF1-QRGG (aa 245–287).
(C). (i) Amino acid sequence of human
AUF1-p37. Shown in boldface italic font are
the polyalanine motifs in exon 1 and the
polyglutamine and RGG repeat motifs in the
C-terminal region. G–K denotes the end of
exon 1. K–C denotes the beginning of exon
6. (ii) The polyalanine region of AUF1 exon 1.
The amino acids removed in the AUF1-Δ21Ala deletant are underlined. (iii) The region
deleted in AUF1-ΔQRGG. (iv) The amino acid
sequence of the AUF1-Ex6+8 (top) and
AUF1-QRGG (bottom) peptides.
Molecular Biology of the Cell

Regulation by mRNA-binding proteins on
3′ UTR elements is analyzed by introducing
the 3′ UTR from regulated mRNA (VEGF,
GLUT1, tumor necrosis factor-α [TNF]) into
the 3′ UTR of reporter genes (firefly luciferase
or green fluorescent protein; Griffin et al.,
2004; Du et al., 2006; Nichols et al., 2010). In
this study, the 3′ UTR of VEGF was placed in
the 3′ UTR of a luciferase reporter, as described previously (Du et al., 2006). In resting
macrophages and other cell types, the 3′
UTR decreases reporter expression (Figure 2;
Du et al., 2006). When cells are stimulated,
reporter expression increases (Du et al.,
FIGURE 6: Deletion of C- and N-terminal regions reduces activity. (A) The AUF1 or AUF12006). This study establishes that AUF1 reguΔQRGG (dQRGG) expression plasmids were cotransfected into RAW-264.7 cells with VEGF-3′
lates 3′ UTR–dependent gene expression by
UTR-Luc (see Figure 5B). Data are normalized to cells transfected with the empty expression
inhibiting VEGF-3′ UTR–dependent luciferase
plasmid pcDNA-3.1 (pcDNA). Deletion of the QRGG region inactivated the inhibitory effect of
reporter expression in RAW-264.7 cells (FigAUF1 on VEGF-3′ UTR-Luc. p < 0.0001, pcDNA vs. AUF1; pcDNA vs. ΔQRGG was not
ure 3). Attempts to knock down AUF1 using
significantly different. p < 0.0001 AUF1 vs. ΔQRGG. (B) Deletion of 21 aa (AUF1-Δ21-Ala, d21)
small inhibitory RNA (siRNA) in RAW-264.7
from the polyalanine region of the full-length AUF1 inactivated AUF1. Effects of the double
deletant (both the polyalanine and the QRGG region deleted) are also shown (d21+dQRGG).
and BMDM cells by transient transfection
p < 0.0001, pcDNA vs. AUF1; pcDNA vs. Δ21 was not significantly different; p < 0.03, pcDNA
was only modestly successful (∼10–30% devs. Δ21+ΔQRGG; p < 0.0001, AUF1 vs. Δ21; p < 0.0001, AUF1 vs. Δ21+ΔQRGG; p < 0.02, Δ21
crease), and although VEGF mRNA and
vs. Δ21+ΔQRGG. Results are normalized to transfection with pcDNA and are representative of
VEGF-3′ UTR-Luc activity increased modestly,
two or more experiments. Shown are mean and SD.
the increase was not significant (unpublished
data). Future studies will use knockdownexpression (Du et al., 2006). Our earlier reports also identified a
stable cell lines in which all cells are affected by siRNA.
similar AU-rich element in the 3′ UTR of GLUT1 mRNA (Griffin et al.,
To understand the mechanism by which AUF1 inhibits VEGF ex2004). Another report showed that the AU-rich element in human
pression, this study investigates the regulatory regions lying N- and
VEGF mRNA regulates gene expression in macrophages by alterC-terminal to the highly conserved RNA-binding domain (Figure 5).
nating secondary structures of RNA (Ray and Fox, 2007). In a renal
Deletion of a polyalanine-rich region in the N-terminus reduced accell carcinoma model, Xin et al. (2012) show that AUF1 binds VEGF
tivity on the VEGF-3′ UTR-Luc reporter (Figure 6B), a result most
AU-rich elements under both normoxia and hypoxia and that regulikely due to reduced protein levels (Figure 7). The N-terminus is
lation of larger isoforms of AUF1 (p42 and p45) is mediated by a
important for protein folding, and loss of N-terminal sequence may
VHL-RNP complex. The AU-rich elements in 3′ UTR regions regulate
reduce the level of successfully folded protein (Peroutka et al., 2011).
gene expression in concert with mRNA-binding proteins (Xu et al.,
The C-terminus of AUF1 contains a region with three repeat RGG
1997). We report here that overexpression of the AUF1 mRNA-bindmotifs. Arginine residues in RGG motifs are enzymatically
ing protein decreases endogenous VEGF protein levels (Figure 1),
establishing the biological significance of AUF1 action on VEGF
gene expression. This study investigates posttranscriptional regulation of VEGF mRNA by the AUF1 mRNA-binding protein.

FIGURE 7: Effects of N- and C-terminal deletions on protein levels.
Lysates of RAW-264.7 cells expressing V5-tagged full-length
AUF1-p37 (FL) or the polyalanine deletant (AUF1-Δ21; d21) or the
QRGG deletant (dQ/RGG) were immunoblotted with anti-V5
antibody. The d21+dQ/RGG deletant lacks both the polyalanine and
the QRGG regions. Results are representative of three experiments.
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FIGURE 8: Effects of cycloheximide inhibition on V5-tagged protein
synthesis. Cultured RAW-264.7 cells were transfected with the
full-length AUF1-V5 protein (AUF), the N-terminal deletant AUF1-d21Ala (d21-Ala), the C-terminal deletant (dQRGG), or the double
deletant (d21-Ala+dQRGG). After 24 h, cells were treated with
cycloheximide for 0, 1, or 4 h. Cell lysates were immunoblotted with
anti-V5 antibody, and protein levels were normalized to α-tubulin
levels. Levels of each protein type are expressed relative to untreated
controls. The change in deletant protein levels was not significantly
different from AUF1 at any time point. Compared to AUF1, the
double-deletant protein levels were decreased by 40% after 4 h, but
the decrease was not significant (p < 0.10). Results are the mean and
SD for three separate experiments.
AUF1 represses VEGF expression
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FIGURE 9: Effects of adenosine dialdehyde on AUF1 protein.
(A) Cells (RAW-264.7) were treated with AdOx (5 µM) for 48 h, and
lysates were immunoblotted for AUF1 isoforms. Loading control was
α-tubulin. (B) The effects of AdOx (5 μM for 48 h) were measured on
RAW-264.7 cells transfected with AUF1 (WT) or AUF1-ΔQRGG-V5
(dQRGG). Triplicate samples were immunoblotted with anti-V5
antibody. WT, dimethyl sulfoxide (DMSO) vs. AdOx, p < 0.0001;
AUF1-ΔQRGG, DMSO vs. AdOx, p < 0.001. Results are normalized to
DMSO treatment and are representative of two or more experiments.
Shown are mean and SD.

dimethylated by protein arginine methyltransferase. This posttranslational modification produces many effects on biological activity
(Bedford and Clarke, 2009; Yu, 2011). Dimethylation of RGG motifs
alters the structure of RNA to which RGG motifs bind but does not
affect the affinity of binding (Raman et al. 2001). Blockade of arginine methylation with adenosine dialdehyde decreased AUF1 protein levels, suggesting a role for methylated arginines in protein
stability (Figure 9). However, deletion of the RGG domain did not
affect protein levels (Figure 7). Together these results suggest that
AdOx produces AUF1 proteins with unmethylated RGG motifs, and
the unmethylated arginines in RGG motifs mark the protein for decay. Loss of the RGG domain inactivated the repressive effects of
AUF1 on the VEGF-3′ UTR reporter (Figure 6A), which suggested
that this region of AUF1 is a candidate for regulatory peptides.
To understand the mechanism of AUF1 action and identify possible regulatory AUF1-RGG peptides, two C-terminal sequences
(AUF1-Ex6+8 and AUF1-QRGG) were studied. Expression of these
AUF1-RGG peptides was anticipated to disrupt protein–protein interactions (DeMaria et al., 1997; He and Schneider, 2006) or interfere with binding of AUF1 to RNA (Raman et al., 2001) and reverse
the inhibitory effect of AUF1 on VEGF gene expression. Surprisingly,
AUF1-RGG peptides reduced VEGF-3′ UTR-Luc activity to the same
degree as full-length AUF1 (Figure 10C). Perhaps more interesting,
expression of AUF1-RGG peptides also reduced endogenous VEGF
protein levels (Figure 10, A and B), reductions that were greater than
found with the full-length AUF1 (Figure 1). A likely mechanism of
action by AUF1-RGG peptides is inactivation of an inhibitory regulator of AUF1. The 14-3-3σ protein binds to a portion of the RGG
domain of AUF1-p37 and -p40 but not to the larger isoforms (He
and Schenider, 2006). The interaction site overlaps with a putative
nuclear localization signal, and 14-3-3σ appears to block localization
1420 | A. Fellows et al.

FIGURE 10: Effects of AUF1-RGG peptides on endogenous VEGF
protein levels. Cultured RAW-264.7 cells were transfected with the
empty parental vector, pcDNA-3.1 (PC), the AUF1-QRGG peptide
vector (QRGG), or the AUF1-6+8 peptide vector (6+8). After 4 h, cells
were treated with LPS for 18 h. Lysates were probed for VEGF and
α-tubulin. (A) Immunoblot for VEGF or α-tubulin. (B) Levels of VEGF
protein normalized to α-tubulin for six experiments. As compared with
pcDNA-3.1, both AUF1-QRGG (p < 0.002) and AUF1-6+8 (p < 0.003)
significantly decreased VEGF protein. (C) Effects of AUF1 peptides on
VEGF-3′ UTR reporter activity. Cells (RAW-264.7) were transfected
with VEGF-3′ UTR-Luc and were cotransfected with pcDNA-3.1, AUF1
(AUF1-p37), or AUF1-RGG peptides (Ex6+8 or QRGG). The luciferase
activity in cell lysates from triplicate wells was read after 24 h. p <
0.0001 for pcDNA vs. AUF, AUF1-Ex6+8, or AUF1-QRGG. No other
comparators were significantly different. Results are normalized to
pcDNA treatment and are representative of two or more experiments.

of AUF1 to the nucleus and increases the effects of AUF1 on mRNA
(He and Schenider, 2006). The 14-3-3σ protein increases cytoplasmic levels of AUF1 and would be predicted to decrease VEGF gene
expression. Interruption of 14-3-3σ by AUF1-RGG peptides would
reverse the action of 14-3-3σ and increase VEGF gene expression.
On the basis of our results, it is more likely that the AUF1-RGG peptides promote or mimic the action of 14-3-3σ. There is no apparent
homology between 14-3-3σ and the AUF1-RGG peptides.
Our results demonstrate that AUF1-RGG peptides derived from
AUF1 can regulate VEGF gene expression. The most likely mechanism for AUF1-RGG peptide action is binding to AUF1 and increasing AUF1 activity. Alternatively, AUF1-RGG peptides may interact
with other regulatory proteins that are binding partners of the RGG
domain of AUF1 (He and Schenider, 2006). Determining how AUF1RGG peptides act to change VEGF gene expression in macrophages
is the focus of ongoing studies. Design of novel biologically active
AUF1 peptides will identify the binding partner and optimize the
pharmacokinetics of this reagent, which may be valuable in reducing VEGF gene expression.

MATERIALS AND METHODS
Reagents
AdOx, LPS, CYX, and MG132 were from Sigma-Aldrich (St. Louis,
MO).

Cell culture
The RAW-264.7 cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and maintained as
Molecular Biology of the Cell

previously described (Griffin et al., 2004; Du et al., 2006). Medium
was low-glucose DMEM supplemented with 10% heat-inactivated
fetal bovine serum (FBS). HEK-293 cells were obtained from ATCC
and maintained in DMEM media supplemented with 10% FBS. Cells
were grown without antibiotics. Cell treatments with LPS, AdOx, or
CYX are described in the text.
BMDMs were obtained from male C57/Bl6 mice. Cells were collected from femoral shafts by flushing with RPMI-1640 containing
10% FBS. The cell suspensions were passed through a 21-gauge
needle in RPMI-1640 to disperse cell clumps and then filtered using
a 70-μm nylon cell strainer to remove bone fragments. Adherent
bone marrow cells (stroma and mature macrophages) were removed
by incubation in tissue culture plates at 37°C overnight. The nonadherent bone marrow cells were then cultured in RPMI-1640, 10%
FBS, 20% L-cell conditioned medium, and gentamicin (50 μg/ml).
The media was supplemented every 2–3 d, and the macrophages
were harvested after 7–10 d.

Cell transfection and luciferase assay
For transfection studies, cultured cells were plated ∼24 h prior to
transfection in 48-well plates with sufficient cells to give ∼50% confluence at the time of transfection. Plasmid DNA was complexed
with Lipofectamine 2000, as described by the manufacturer (Invitrogen, Carlsbad, CA). Cells were transfected with luciferase constructs
at ∼0.2 μg of plasmid DNA per 100,000 cells. Transfection efficiency
under experimental conditions was monitored in separate experiments by cotransfection with 1) a plasmid expressing firefly luciferase
plus 2) sufficient plasmid expressing Renilla sea pansy luciferase
(pRL-SV40; Promega, Madison, WI) to give 2–10% of the firefly reporter activity. Correction for Renilla activity did not change the
variation in the firefly data (Supplemental Table S2). Cells were lysed
after 18–24 h with Cell Culture Lysis Reagent or Passive Lysis Buffer
(for Renilla) (Promega) and the lysate frozen at −80°C. The luciferase
activity in the lysate of ∼20,000 cells (20 μl of a 100-μl lysate of a well
from a 48-well plate) was determined following addition of luciferin
substrate (Promega) in LMax (Molecular Dynamics, Sunnyvale, CA)
or Centro LB 960 (Berthold, Oak Ridge, TN) luminometers. Transfections were performed in triplicate or quadruplicate. The effect of
AUF1-binding proteins on VEGF-3′ UTR–dependent luciferase production was measured by cotransfecting the AUF1 expression plasmids (pcDNA-3.1 is the parent vector) together with luciferase reporter plasmids. Reporter activity of cotransfected cells is expressed
relative to the activity of cells transfected with the empty expression
plasmid, pcDNA-3.1. To determine whether experimental conditions affected the luciferase reporter, parallel wells were transfected
with the parent luciferase (3.1-luciferase) instead of the VEGF-3′
UTR-luciferase. Experimental conditions did not affect the parent
luciferase (Supplemental Table S1). All experiments were performed
two or more times.
For transfection studies of BMDMs, cells were suspended with
trypsin and counted. Cells were incubated with plasmid DNA and
electroporated using the Amaxa BMDM buffer, as described by the
manufacturer (Lonza, Basel, Switzerland). Cells were lysed after 24 h
and luciferase activity measured in 20 μl of cell lysate.

Immunoblotting
Total protein was measured using either Bradford assay (Bio-Rad,
Hercules, CA) or bicinchoninic acid (Pierce, Thermo Fisher Scientific,
Rockford, IL). Equal amounts of protein were separated on Invitrogen 4–12% Tris-glycine gels and transferred to polyvinylidene fluoride membranes using the I-blot system (Invitrogen) or by wet transfer (Bio-Rad). In some experiments, all four AUF1 isoforms could be
resolved using gradient gels and the I-Blot transfer system. Precision
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Plus dual-color protein standard (Bio-Rad) was used to determine
molecular weight. Blots were probed with antibodies to AUF1
(Millipore, Billerica, MA), V5 (Invitrogen), or Tie2 (Santa Cruz
Biotechnology, Santa Cruz, CA). Blots were developed with horseradish peroxidase (HRP) secondary antibodies (mouse and rabbit
secondary HRP antibodies were from Sigma-Aldrich) using X-Omat
film (Kodak, Rochester, NY) or imaged using the VersaDoc system
(Bio-Rad). Protein levels were quantitated by scanning immunoblots
or digital images. The image intensities were measured using
ImageJ (National Institutes of Health, Bethesda, MD). Protein bands
were normalized to α-tubulin (Sigma-Aldrich).

RNA isolation and real-time PCR
Total cellular RNA was isolated using the QiaShredder columns and
the RNeasy kit (Qiagen, Valencia, CA). The RNA was quantified using
a NanoDrop (Thermo Fisher Scientific, Waltham, MA). Next, 1–5 μg
of RNA was treated with Turbo-DNA-free (Ambion, Austin, TX), and
cDNA was created using the Maxima First Strand cDNA kit (Fermentas, Glen Burnie, MD). Real-time PCR was performed with RT2 Real
Time SYBR Master Mix (SABiosciences, Frederick, MD), using standard conditions. Levels of mRNA (Ct) were normalized to the level of
18S RNA. All samples were run in triplicate. Melting curves were performed to confirm single PCR products. Primer pairs are as follows.
Mouse VEGF: sense, aagtgatcaagttcatggatgtcta; antisense, aagctcatctctcctatgtgctg. Mouse hexokinase 2: sense, aactgagtttgacagagagatcgac; antisense, gtcttcaatatccgagacatctttg. Mouse GLUT1:
sense, caatgctgtgttctactactcaacg; antisense, gatgctcagataggacatccaag. 18S rRNA: sense, gcatatgcttgtctcaaagattaag; antisense, tattagctctagaattaccacagttatcca. Primer pairs cross introns, except the
18S RNA gene, which lacks introns. To verify the size of PCR products, amplicons were separated on a 2% NuSieve DNA gels, stained
with Syber Gold (Molecular Probes, Invitrogen), and imaged by
VersaDoc.

AUF1/mRNA immunoprecipitation
RAW-264.7 cells were plated with 1 × 107 cells in 10-cm plates. The
next day, the cells were lysed in 1 ml of lysis buffer (LB; 10 mM TrisHCl, pH 8.0, 1.5 mM MgCl2, 100 mM NaCl, 0.5% Tween-20, complete protease cocktail [Roche, Indianapolis, IN]) plus RNAse Protect
(Sigma-Aldrich). Lysate was precleared with 50 μl of equilibrated
protein A magnetic beads (Millipore). A 20-μg amount of antibody
to AUF1 or Tie2 (control) was bound to beads. Antibody-bound
beads were incubated with 300 μg of total cellular protein overnight
rotating at 4°C. Beads were washed repeatedly with LB, and RNA
was purified (RNeasy). Levels of mRNA were measured by PCR, followed by DNA gel electrophoresis or by real-time PCR.

Plasmid construction
AUF1 expression constructs. Human AUF1-p37 and AUF1-p40
expression plasmids were created using AUF1 plasmids as template
(generous gift of Robert Schneider, New York University, New York,
NY). Coding regions were amplified by PCR and cloned into pcDNA3.1-V5-His (Invitrogen). The parental vector control for AUF1
overexpression experiments was pcDNA-3.1. The polyalanine
AUF1-p37 deletant (∆21-Ala; aa 13–33 deleted) was created by lowstringency (low annealing temperature) whole-plasmid PCR. A
deletion construct of the C-terminal region of AUF1-p37 (∆QRGG,
aa 206–278 deleted) was generated using the PCR-based
QuikChange Mutagenesis Kit (Stratagene, Santa Clara, CA). The
∆QRGG construct retains a hybrid RGG motif at the site of the
deletion. A double deletant (∆21-Ala+∆QRGG) was created by
using PCR cloning using ∆21-Ala as template. Fragments of AUF1
AUF1 represses VEGF expression
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were created by PCR and cloned into pcDNA-3.1-V5-His. The
AUF1-Ex6+8 construct includes the region encoded by exons 6 and
8 (aa 234–287), and AUF1-QRGG includes the region from the
polyglutamine motif to the C-terminus (aa 244–287). The sense
primer introduced an initiating methionine codon. Amino acid
numbering is based on human AUF1-p37, GenBank reference file
NM_001003810. All AUF1 C-terminal fragments were cloned using
the pcDNA-3.1-V5-His cloning construct (Invitrogen). DNA
sequencing on both strands verified the integrity of all constructs.
Luciferase constructs. The parental (3.1-luciferase) and full-length
VEGF-3′ UTR-luciferase (mouse VEGF-3′ UTR, nt-209-1747, GenBank
AF317892) expression plasmids were constructed as previously
described (Du et al., 2006). Briefly, the luciferase gene from pGL3
(Promega) was cloned into pcDNA-3.1. Then the VEGF 3′ UTR was
cloned into the 3′ UTR of the luciferase gene.

Statistical analysis
Experimental conditions were analyzed in triplicate or quadruplicate. Results are shown as mean and SD. Significant differences
in results were determined by t test using GraphPad Prism
(GraphPad Software, La Jolla, CA), and p < 0.05 was considered
significant.
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